CV Sciences, Inc. and its peers
1 companies side by side: each figure with its date and source, its rank in the group and its percentile in its sector and country.
Companies in the group
Up to 12. Remove or re-base from the table's column heads.
Keep this group
Save it for yourself or, in a team, for everyone in it.
Suggested peers of CV Sciences, Inc.#
Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.
- Healthy Extracts Inc.HYEX · 🇺🇸 USASame industry: Pharmaceutical · Similar size: $19 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $19 M (last known, Jul 30, 2023) · revenue $5 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)+ Add
- TherapeuticsMD, Inc.TXMD · 🇺🇸 USASame industry: Pharmaceutical · Similar size: $23 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $23 M (Oct 14, 2026) · revenue $3 M (year to December 2025)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)+ Add
- Cosmos HoldingsCOSM · 🇺🇸 USASame industry: Pharmaceutical · Similar size: $28 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $28 M (Oct 30, 2026) · revenue $65 M (year to December 2025)98 of 100 (industry or sector 50 + size 28 + country 15 + figures on file 5)+ Add
- Neurogene Inc.NGNE · 🇺🇸 USASame industry: Pharmaceutical · Similar size: $30 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $30 M (last known, Jul 30, 2023) · revenue $0 M (year to December 2025)97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)+ Add
- Rockwell Medical, Inc.RMTI · 🇺🇸 USASame industry: Pharmaceutical · Similar size: $32 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $32 M (Oct 16, 2026) · revenue $69 M (year to December 2025)97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)+ Add
- Resonate Blends, Inc.KOAN · 🇺🇸 USASame industry: Pharmaceutical · Similar size: $12 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $12 M (last known, Jan 7, 2022) · revenue $2 M (year to December 2024)97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)+ Add
- Scynexis, Inc.SCYX · 🇺🇸 USASame industry: Pharmaceutical · Similar size: $38 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $38 M (Oct 30, 2026) · revenue $21 M (year to December 2025)96 of 100 (industry or sector 50 + size 26 + country 15 + figures on file 5)+ Add
- Bonk, Inc.BNKK · 🇺🇸 USASame industry: Pharmaceutical · Similar size: $10 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $10 M (Oct 30, 2026) · revenue $2 M (year to December 2025)96 of 100 (industry or sector 50 + size 26 + country 15 + figures on file 5)+ Add
- Elite Pharmaceuticals, Inc.ELTP · 🇺🇸 USASame industry: Pharmaceutical · Similar size: $42 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $42 M (last known, Jan 7, 2022) · revenue $149 M (year to March 2026)95 of 100 (industry or sector 50 + size 25 + country 15 + figures on file 5)+ Add
- Weed Inc.BUDZ · 🇺🇸 USASame industry: Pharmaceutical · Similar size: $9 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $9 M (last known, Jul 30, 2023)95 of 100 (industry or sector 50 + size 25 + country 15 + figures on file 5)+ Add
- Medmen Enterprises Inc.MMEN.CN · 🇺🇸 USASame industry: Pharmaceutical · Similar size: $21 M market cap against $20 M · Same country: USAMarket cap $21 M (last known, Jan 5, 2024)95 of 100 (industry or sector 50 + size 30 + country 15)+ Add
- Cansortium Inc.TIUM-U.CN · 🇺🇸 USASame industry: Pharmaceutical · Similar size: $19 M market cap against $20 M · Same country: USAMarket cap $19 M (last known, Jan 5, 2024)95 of 100 (industry or sector 50 + size 30 + country 15)+ Add
CV Sciences, Inc.: the market cap on file is more than 60 days old or a last known value (no market-data feed for its exchange yet), so its valuation multiples and yields are shown but not ranked.
Side by side#
Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.
| Measure | CV Sciences, Inc.base CVSI · 🇺🇸 US Percentile in Healthcare Percentile in USA | Group median |
|---|---|---|
| Size | ||
| Market cap (Better neither way: ranked highest first) | $20 Mlast known, Jan 7, 2022 · Market dataLast known value: no current oneonly one with it | $20 M— |
| Revenue (Better neither way: ranked highest first) | $14 MFY2025 · SEConly one with it | $14 M— |
| Net income (Higher is better) | $-1 MFY2025 · SEConly one with it | $-1 M— |
| Employees (Better neither way: ranked highest first) | 44December 31, 2025 · Profileonly one with it | 44— |
| Growth | ||
| Revenue growth (Higher is better) | -12.2%FY2025 · SEConly one with it14th10th | -12.2%— |
| Revenue growth, 3 years a year (Higher is better) | -5.2%FY2025 · SEConly one with it16th18th | -5.2%— |
| Margins and returns | ||
| Gross margin (Higher is better) | 49.0%FY2025 · SEConly one with it35th62nd | 49.0%— |
| Operating margin (Higher is better) | -3.4%FY2025 · SEConly one with it53rd34th | -3.4%— |
| Net margin (Higher is better) | -7.0%FY2025 · SEConly one with it51st30th | -7.0%— |
| Free cash flow margin (Higher is better) | -3.8%FY2025 · SEConly one with it46th27th | -3.8%— |
| Return on equity (Higher is better) | -58.7%FY2025 · SEConly one with it39th16th | -58.7%— |
| Financial strength | ||
| Debt to equity (Lower is better) | 1.1×FY2025 · SEConly one with it77th71st | 1.1×— |
| Piotroski F-score (Higher is better) | 6 of 9FY2025 · SEConly one with it | 6.0 of 9— |
| Scorecard | ||
| Scorecard (Higher is better) | 3 of 15FY2025 · Scorecardonly one with it | 20% passed— |
| Growth checks (Higher is better) | 1 of 6FY2025 · Scorecardonly one with it | 17% passed— |
| Profitability checks (Higher is better) | 1 of 5FY2025 · Scorecardonly one with it | 20% passed— |
| Financial health checks (Higher is better) | 1 of 3FY2025 · Scorecardonly one with it | 33% passed— |
| Shareholder returns checks (Higher is better) | 0 of 1FY2025 · Scorecardonly one with it | 0% passed— |
Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = CV Sciences, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.
Where each stands in its sector and country: Operating margin#
The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.
| Company | Operating margin | In its sector | In its country |
|---|---|---|---|
| CV Sciences, Inc. | -3.4%FY2025 | 53rd percentile in Healthcaremedian -7.7%, 674 companies | 34th percentile in USAmedian 3.5%, 2,594 companies |
Revenue by fiscal year, and the rank in the group#
Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).
Revenue
Rank in the group
Ranks need two fiscal years with the figure for at least two of these companies.
| Fiscal year | CV Sciences, Inc. |
|---|---|
| 2025 | $14 MSEC |
| 2024 | $16 MSEC |
| 2023 | $16 MSEC |
| 2022 | $16 MSEC |
| 2021 | $20 MSEC |
| 2020 | $24 MSEC |
| 2019 | $54 MSEC |
| 2018 | $48 MSEC |
| 2017 | $21 MSEC |
| 2016 | $11 MSEC |
| 2015 | $12 MSEC |
| 2014 | $10 MSEC |
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.